OA05.02 Acute SIV Induces BHLH gene variants prior to adaptive natural killer cell formationOral Abstract SessionInnate and trained immunity
OA05.01 Role of HLA-E antigen presentation on NK control of HIV infection Oral Abstract SessionInnate and trained immunity
OA04.05LB Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP)Oral Abstract SessionClinical trial results
OA04.04 Design and testing of a cabotegravir reservoir implant for HIV preventionOral Abstract SessionDelivery technologies: novel approaches, formulation and multi-purpose
OA04.03 Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participantsOral Abstract SessionPharmacology/PK and PD studies
OA04.02 High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamideOral Abstract SessionPreclinical studies for HIV prevention
OA04.01 User assessment of a microarray patch for HIV PrEP and as a multipurpose prevention technology for HIV and pregnancy prevention: perspectives from Uganda and South AfricaOral Abstract SessionBehavioural and social science research
OA03.05LB HIV-1 bnAb M4008_N1 targets a novel site of vulnerability at the V3 crownOral Abstract SessionBroadly neutralizing antibodies
OA03.04LB Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085)Oral Abstract SessionBroadly neutralizing antibodies
OA03.03 Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)Oral Abstract SessionBroadly neutralizing antibodies
seek-warrow-warrow-eseek-e421 - 430 of 444 items